Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2015, Article ID 851945, 11 pages
http://dx.doi.org/10.1155/2015/851945
Review Article

Innate and Adaptive Immunity in Calcific Aortic Valve Disease

1Laboratoire d’Études Moléculaires des Valvulopathies (LEMV), Groupe de Recherche en Valvulopathies (GRV), Quebec Heart and Lung Institute/Research Center, Department of Surgery, Laval University, QC, Canada
2Institut de Cardiologie et de Pneumologie de Québec, 2725 Chemin Sainte-Foy, Québec, QC, Canada G1V 4G5

Received 14 August 2014; Accepted 16 September 2014

Academic Editor: Giacomina Brunetti

Copyright © 2015 Patrick Mathieu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Mathieu, M. C. Boulanger, and R. Bouchareb, “Molecular biology of calcific aortic valve disease: towards new pharmacological therapies,” Expert Review of Cardiovascular Therapy, vol. 12, no. 7, pp. 851–862, 2014. View at Google Scholar
  2. N. M. Rajamannan, F. J. Evans, E. Aikawa et al., “Calcific aortic valve disease: not simply a degenerative process: a review and agenda for research from the national heart and lung and blood institute aortic stenosis working group. Executive summary: calcific aortic valve disease—2011 update,” Circulation, vol. 124, no. 16, pp. 1783–1791, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. V. Persy and P. D'Haese, “Vascular calcification and bone disease: the calcification paradox,” Trends in Molecular Medicine, vol. 15, no. 9, pp. 405–416, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. R. Bouchareb, M.-C. Boulanger, D. Fournier, P. Pibarot, Y. Messaddeq, and P. Mathieu, “Mechanical strain induces the production of spheroid mineralized microparticles in the aortic valve through a RhoA/ROCK-dependent mechanism,” Journal of Molecular and Cellular Cardiology, vol. 67, pp. 49–59, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. K. D. O'Brien, D. D. Reichenbach, S. M. Marcovina, J. Kuusisto, C. E. Alpers, and C. M. Otto, “Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 16, no. 4, pp. 523–532, 1996. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Coté, A. Mahmut, Y. Bosse et al., “Inflammation is associated with the remodeling of calcific aortic valve disease,” Inflammation, vol. 36, no. 3, pp. 573–581, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. J.-H. Chen and C. A. Simmons, “Cell-matrix interactions in the pathobiology of calcific aortic valve disease: critical roles for matricellular, matricrine, and matrix mechanics cues,” Circulation Research, vol. 108, no. 12, pp. 1510–1524, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. J. T. Butcher, C. A. Simmons, and J. N. Warnock, “Mechanobiology of the aortic heart valve,” Journal of Heart Valve Disease, vol. 17, no. 1, pp. 62–73, 2008. View at Google Scholar · View at Scopus
  9. P. F. Davies, A. G. Passerini, and C. A. Simmons, “Aortic valve: turning over a new leaf(let) in endothelial phenotypic heterogeneity,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 8, pp. 1331–1333, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Mohty, P. Pibarot, J.-P. Després et al., “Association between plasma LDL particle size, valvular accumulation of oxidized LDL, and inflammation in patients with aortic stenosis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 1, pp. 187–193, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. C. M. Otto, J. Kuusisto, D. D. Reichenbach, A. M. Gown, and K. D. O'Brien, “Characterization of the early lesion of 'degenerative' valvular aortic stenosis: histological and immunohistochemical studies,” Circulation, vol. 90, no. 2, pp. 844–853, 1994. View at Publisher · View at Google Scholar · View at Scopus
  12. I. Steiner, P. Kašparová, A. Kohout, and J. Dominik, “Bone formation in cardiac valves: a histopathological study of 128 cases,” Virchows Archiv, vol. 450, no. 6, pp. 653–657, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. A. R. Brasier, “The nuclear factor-B-interleukin-6 signalling pathway mediating vascular inflammation,” Cardiovascular Research, vol. 86, no. 2, pp. 211–218, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. F. Liu, Y. Xia, A. S. Parker, and I. M. Verma, “IKK biology,” Immunological Reviews, vol. 246, no. 1, pp. 239–253, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. A. A. Beg, T. S. Finco, P. V. Nantermet, and A. S. Baldwin Jr., “Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of IκBα: a mechanism for NF-κB activation,” Molecular and Cellular Biology, vol. 13, no. 6, pp. 3301–3310, 1993. View at Google Scholar · View at Scopus
  16. K. Hochrainer, G. Racchumi, and J. Anrather, “Site-specific phosphorylation of the p65 protein subunit mediates selective gene expression by differential NF-κB and RNA polymerase II promoter recruitment,” The Journal of Biological Chemistry, vol. 288, no. 1, pp. 285–293, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. C. C. Ghosh, S. Ramaswami, A. Juvekar et al., “Gene-specific repression of proinflammatory cytokines in stimulated human macrophages by nuclear IκBα,” Journal of Immunology, vol. 185, no. 6, pp. 3685–3693, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Zhong, R. E. Voll, and S. Ghosh, “Phosphorylation of NF-κB p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300,” Molecular Cell, vol. 1, no. 5, pp. 661–671, 1998. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Jamaluddin, S. Wang, I. Boldogh, B. Tian, and A. R. Brasier, “TNF-α-induced NF-κB/RelA Ser276 phosphorylation and enhanceosome formation is mediated by an ROS-dependent PKAc pathway,” Cellular Signalling, vol. 19, no. 7, pp. 1419–1433, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. E. Branchetti, R. Sainger, P. Poggio et al., “Antioxidant enzymes reduce DNA damage and early activation of valvular interstitial cells in aortic valve sclerosis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 33, no. 2, pp. e66–e74, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. G. Xiao, A. Fong, and S.-C. Sun, “Induction of p100 processing by NF-κB-inducing kinase involves docking IκB kinase α (IKKα) to p100 and IKKα-mediated phosphorylation,” Journal of Biological Chemistry, vol. 279, no. 29, pp. 30099–30105, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. M. D. Morrison, W. Reiley, M. Zhang, and S.-C. Sun, “An atypical Tumor Necrosis Factor (TNF) receptor-associated factor-binding motif of B cell-activating factor belonging to the TNF Family (BAFF) receptor mediates induction of the noncanonical NF-κB signaling pathway,” Journal of Biological Chemistry, vol. 280, no. 11, pp. 10018–10024, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. D. El Husseini, M.-C. Boulanger, A. Mahmut et al., “P2Y2 receptor represses IL-6 expression by valve interstitial cells through Akt: implication for calcific aortic valve disease,” Journal of Molecular and Cellular Cardiology, vol. 72, pp. 146–156, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. N. Côté, D. El Husseini, A. Pépin et al., “ATP acts as a survival signal and prevents the mineralization of aortic valve,” Journal of Molecular and Cellular Cardiology, vol. 52, no. 5, pp. 1191–1202, May 2012. View at Publisher · View at Google Scholar
  25. P. Mathieu, P. Voisine, A. Pépin, R. Shetty, N. Savard, and F. Dagenais, “Calcification of human valve interstitial cells is dependent on alkaline phosphatase activity,” Journal of Heart Valve Disease, vol. 14, no. 3, pp. 353–357, 2005. View at Google Scholar · View at Scopus
  26. N. Côté, D. El Husseini, A. Pépin et al., “Inhibition of ectonucleotidase with ARL67156 prevents the development of calcific aortic valve disease in warfarin-treated rats,” European Journal of Pharmacology, vol. 689, no. 1–3, pp. 139–146, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. P. Mathieu, “Pharmacology of ectonucleotidases: relevance for the treatment of cardiovascular disorders,” European Journal of Pharmacology, vol. 696, no. 1–3, pp. 1–4, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. D. El Husseini, M.-C. Boulanger, D. Fournier et al., “High expression of the Pi-transporter SLC20A1/Pit1 in calcific aortic valve disease promotes mineralization through regulation of Akt-1,” PLoS ONE, vol. 8, no. 1, Article ID e53393, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. P. Mathieu, I. Lemieux, and J.-P. Després, “Obesity, inflammation, and cardiovascular risk,” Clinical Pharmacology & Therapeutics, vol. 87, no. 4, pp. 407–416, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. G. J. Mahler, E. J. Farrar, and J. T. Butcher, “Inflammatory cytokines promote mesenchymal transformation in embryonic and adult valve endothelial cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 33, no. 1, pp. 121–130, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. T. Wada, T. Nakashima, N. Hiroshi, and J. M. Penninger, “RANKL-RANK signaling in osteoclastogenesis and bone disease,” Trends in Molecular Medicine, vol. 12, no. 1, pp. 17–25, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. P. Mathieu, P. Poirier, P. Pibarot, I. Lemieux, and J.-P. Després, “Visceral obesity the link among inflammation, hypertension, and cardiovascular disease,” Hypertension, vol. 53, no. 4, pp. 577–584, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. Z. Yu, K. Seya, K. Daitoku, S. Motomura, I. Fukuda, and K.-I. Furukawa, “Tumor necrosis factor-α accelerates the calcification of human aortic valve interstitial cells obtained from patients with calcific aortic valve stenosis via the BMP2-Dlx5 pathway,” Journal of Pharmacology and Experimental Therapeutics, vol. 337, no. 1, pp. 16–23, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. J. J. Kaden, R. Kiliç, A. Sarikoç et al., “Tumor necrosis factor alpha promotes an osteoblast-like phenotype in human aortic valve myofibroblasts: a potential regulatory mechanism of valvular calcification,” International Journal of Molecular Medicine, vol. 16, no. 5, pp. 869–872, 2005. View at Google Scholar · View at Scopus
  35. R. A. Black, C. T. Rauch, C. J. Kozlosky et al., “A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells,” Nature, vol. 385, no. 6618, pp. 729–733, 1997. View at Publisher · View at Google Scholar · View at Scopus
  36. H. Hsu, J. Xiong, and D. V. Goeddel, “The TNF receptor 1-associated protein TRADD signals cell death and NF-κB activation,” Cell, vol. 81, no. 4, pp. 495–504, 1995. View at Publisher · View at Google Scholar · View at Scopus
  37. H. Hsu, H.-B. Shu, M.-G. Pan, and D. V. Goeddel, “TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways,” Cell, vol. 84, no. 2, pp. 299–308, 1996. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Bertazzo, E. Gentleman, K. L. Cloyd, A. H. Chester, M. H. Yacoub, and M. M. Stevens, “Nano-analytical electron microscopy reveals fundamental insights into human cardiovascular tissue calcification,” Nature Materials, vol. 12, no. 6, pp. 576–583, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Adhikari, M. Xu, and Z. J. Chen, “Ubiquitin-mediated activation of TAK1 and IKK,” Oncogene, vol. 26, no. 22, pp. 3214–3226, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. H.-L. Lee, K. M. Woo, H.-M. Ryoo, and J.-H. Baek, “Tumor necrosis factor-α increases alkaline phosphatase expression in vascular smooth muscle cells via MSX2 induction,” Biochemical and Biophysical Research Communications, vol. 391, no. 1, pp. 1087–1092, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. Z. Al-Aly, J.-S. Shao, C.-F. Lai et al., “Aortic Msx2-Wnt calcification cascade is regulated by TNF-α-dependent signals in diabetic Ldlr−/− mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 12, pp. 2589–2596, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. K. Isoda, T. Matsuki, H. Kondo, Y. Iwakura, and F. Ohsuzu, “Deficiency of interleukin-1 receptor antagonist induces aortic valve disease in BALB/c Mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 4, pp. 708–715, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. J. J. Kaden, C.-E. Dempfle, R. Grobholz et al., “Interleukin-1 beta promotes matrix metalloproteinase expression and cell proliferation in calcific aortic valve stenosis,” Atherosclerosis, vol. 170, no. 2, pp. 205–211, 2003. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Galeone, G. Brunetti, A. Oranger et al., “Aortic valvular interstitial cells apoptosis and calcification are mediated by TNF-related apoptosis-inducing ligand,” International Journal of Cardiology, vol. 169, no. 4, pp. 296–304, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. L. Lum, B. R. Wong, R. Josien et al., “Evidence for a role of a tumor necrosis factor-α (TNF-α)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival,” Journal of Biological Chemistry, vol. 274, no. 19, pp. 13613–13618, 1999. View at Publisher · View at Google Scholar · View at Scopus
  46. B. R. Wong, R. Josien, S. Y. Lee, M. Vologodskaia, R. M. Steinman, and Y. Choi, “The TRAF family of signal transducers mediates NF-κB activation by the TRANCE receptor,” The Journal of Biological Chemistry, vol. 273, no. 43, pp. 28355–28359, 1998. View at Publisher · View at Google Scholar · View at Scopus
  47. B. R. Wong, D. Besser, N. Kim et al., “TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src,” Molecular Cell, vol. 4, no. 6, pp. 1041–1049, 1999. View at Publisher · View at Google Scholar · View at Scopus
  48. W. S. Simonet, D. L. Lacey, C. R. Dunstan et al., “Osteoprotegerin: a novel secreted protein involved in the regulation of bone density,” Cell, vol. 89, no. 2, pp. 309–319, 1997. View at Publisher · View at Google Scholar · View at Scopus
  49. N. Bucay, I. Sarosi, C. R. Dunstan et al., “Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification,” Genes and Development, vol. 12, no. 9, pp. 1260–1268, 1998. View at Publisher · View at Google Scholar · View at Scopus
  50. J. J. Kaden, S. Bickelhaupt, R. Grobholz et al., “Receptor activator of nuclear factor κB ligand and osteoprotegerin regulate aortic valve calcification,” Journal of Molecular and Cellular Cardiology, vol. 36, no. 1, pp. 57–66, 2004. View at Publisher · View at Google Scholar · View at Scopus
  51. R. M. Weiss, D. D. Lund, Y. Chu et al., “Osteoprotegerin inhibits aortic valve calcification and preserves valve function in hypercholesterolemic mice,” PLoS ONE, vol. 8, no. 6, Article ID e65201, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. K. D. O'Brien, D. M. Shavelle, M. T. Caulfield et al., “Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma,” Circulation, vol. 106, no. 17, pp. 2224–2230, 2002. View at Publisher · View at Google Scholar · View at Scopus
  53. S. Helske, K. A. Lindstedt, M. Laine et al., “Induction of local angiotensin II-producing systems in stenotic aortic valves,” Journal of the American College of Cardiology, vol. 44, no. 9, pp. 1859–1866, 2004. View at Publisher · View at Google Scholar · View at Scopus
  54. E. Wypasek, J. Natorska, G. Grudzień, G. Filip, J. Sadowski, and A. Undas, “Mast cells in human stenotic aortic valves are associated with the severity of stenosis,” Inflammation, vol. 36, no. 2, pp. 449–456, 2013. View at Publisher · View at Google Scholar · View at Scopus
  55. N. Côté, P. Pibarot, A. Pépin et al., “Oxidized low-density lipoprotein, angiotensin II and increased waist cirumference are associated with valve inflammation in prehypertensive patients with aortic stenosis,” International Journal of Cardiology, vol. 145, no. 3, pp. 444–449, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. N. Côté, A. Mahmut, D. Fournier et al., “Angiotensin receptor blockers are associated with reduced fibrosis and interleukin-6 expression in calcific aortic valve disease,” Pathobiology, vol. 81, no. 1, pp. 15–24, 2013. View at Publisher · View at Google Scholar · View at Scopus
  57. R. Capoulade, M.-A. Clavel, P. Mathieu et al., “Impact of hypertension and renin-angiotensin system inhibitors in aortic stenosis,” European Journal of Clinical Investigation, vol. 43, no. 12, pp. 1262–1272, 2013. View at Publisher · View at Google Scholar · View at Scopus
  58. T. Fujisaka, M. Hoshiga, J. Hotchi et al., “Angiotensin II promotes aortic valve thickening independent of elevated blood pressure in apolipoprotein-E deficient mice,” Atherosclerosis, vol. 226, no. 1, pp. 82–87, 2013. View at Publisher · View at Google Scholar · View at Scopus
  59. K. Arishiro, M. Hoshiga, N. Negoro et al., “Angiotensin receptor-1 blocker inhibits atherosclerotic changes and endothelial disruption of the aortic valve in hypercholesterolemic rabbits,” Journal of the American College of Cardiology, vol. 49, no. 13, pp. 1482–1489, 2007. View at Publisher · View at Google Scholar · View at Scopus
  60. L. M. McAllister-Lucas, J. Ruland, K. Siu et al., “CARMA3/Bcl10/MALT1-dependent NF-κB activation mediates angiotensin II-responsive inflammatory signaling in nonimmune cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 1, pp. 139–144, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. S. Choudhary, M. Lu, R. Cui, and A. R. Brasier, “Involvement of a novel Rac/RhoA guanosine triphosphatase-nuclear factor-κB inducing kinase signaling pathway mediating angiotensin II-induced RelA transactivation,” Molecular Endocrinology, vol. 21, no. 9, pp. 2203–2217, 2007. View at Publisher · View at Google Scholar · View at Scopus
  62. C. Y. Sasaki, T. J. Barberi, P. Ghosh, and D. L. Longo, “Phosphorylation of Re1A/p65 on serine 536 defines an IκBα- independent NF-κB pathway,” Journal of Biological Chemistry, vol. 280, no. 41, pp. 34538–34547, 2005. View at Publisher · View at Google Scholar · View at Scopus
  63. D. Bosisio, I. Marazzi, A. Agresti, N. Shimizu, M. E. Bianchi, and G. Natoli, “A hyper-dynamic equilibrium between promoter-bound and nucleoplasmic dimers controls NF-κB-dependent gene activity,” The EMBO Journal, vol. 25, no. 4, pp. 798–810, 2006. View at Publisher · View at Google Scholar · View at Scopus
  64. M. Olsson, J. Thyberg, and J. Nilsson, “Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 5, pp. 1218–1222, 1999. View at Publisher · View at Google Scholar · View at Scopus
  65. M. Briand, I. Lemieux, J. G. Dumesnil et al., “Metabolic syndrome negatively influences disease progression and prognosis in aortic stenosis,” Journal of the American College of Cardiology, vol. 47, no. 11, pp. 2229–2236, 2006. View at Publisher · View at Google Scholar · View at Scopus
  66. A. Mahmut, M.-C. Boulanger, D. Fournier et al., “Lipoprotein lipase in aortic valve stenosis is associated with lipid retention and remodelling,” European Journal of Clinical Investigation, vol. 43, no. 6, pp. 570–578, 2013. View at Publisher · View at Google Scholar · View at Scopus
  67. H. Derbali, Y. Bosse, N. Cote et al., “Increased biglycan in aortic valve stenosis leads to the overexpression of phospholipid transfer protein via toll-like receptor 2,” The American Journal of Pathology, vol. 176, no. 6, pp. 2638–2645, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. R. Song, Q. Zeng, L. Ao et al., “Biglycan induces the expression of osteogenic factors in human aortic valve interstitial cells via toll-like receptor-2,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 32, no. 11, pp. 2711–2720, 2012. View at Publisher · View at Google Scholar · View at Scopus
  69. R. Song, L. Ao, K.-S. Zhao et al., “Soluble biglycan induces the production of ICAM-1 and MCP-1 in human aortic valve interstitial cells through TLR2/4 and the ERK1/2 pathway,” Inflammation Research, vol. 63, no. 9, pp. 703–710, 2014. View at Publisher · View at Google Scholar · View at Scopus
  70. N. A. Nadlonek, J. H. Lee, M. J. Weyant, X. Meng, and D. A. Fullerton, “Ox-LDL induces PiT-1 expression in human aortic valve interstitial cells,” Journal of Surgical Research, vol. 184, no. 1, pp. 6–9, 2013. View at Publisher · View at Google Scholar · View at Scopus
  71. Q. Zeng, R. Song, L. Ao et al., “Notch1 promotes the pro-osteogenic response of human aortic valve interstitial cells via modulation of erk1/2 and nuclear factor-κb activation,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 33, no. 7, pp. 1580–1590, 2013. View at Publisher · View at Google Scholar · View at Scopus
  72. Q. Zeng, C. Jin, L. Ao et al., “Cross-talk between the toll-like receptor 4 and notch1 pathways augments the inflammatory response in the interstitial cells of stenotic human aortic valves,” Circulation, vol. 126, no. 11, supplement 1, pp. S222–S230, 2012. View at Publisher · View at Google Scholar · View at Scopus
  73. V. Garg, A. N. Muth, J. F. Ransom et al., “Mutations in NOTCH1 cause aortic valve disease,” Nature, vol. 437, no. 7056, pp. 270–274, 2005. View at Publisher · View at Google Scholar · View at Scopus
  74. V. Nigam and D. Srivastava, “Notch1 represses osteogenic pathways in aortic valve cells,” Journal of Molecular and Cellular Cardiology, vol. 47, no. 6, pp. 828–834, 2009. View at Publisher · View at Google Scholar · View at Scopus
  75. N. Osman, K. J. Grande-Allen, M. L. Ballinger et al., “Smad2-dependent glycosaminoglycan elongation in aortic valve interstitial cells enhances binding of LDL to proteoglycans,” Cardiovascular Pathology, vol. 22, no. 2, pp. 146–155, 2013. View at Publisher · View at Google Scholar · View at Scopus
  76. J. D. Miller, Y. Chu, R. M. Brooks, W. E. Richenbacher, R. Peña-Silva, and D. D. Heistad, “Dysregulation of antioxidant mechanisms contributes to increased oxidative stress in calcific aortic valvular stenosis in humans,” Journal of the American College of Cardiology, vol. 52, no. 10, pp. 843–850, 2008. View at Publisher · View at Google Scholar · View at Scopus
  77. H. Li and U. Forstermann, “Uncoupling of endothelial NO synthase in atherosclerosis and vascular disease,” Current Opinion in Pharmacology, vol. 13, no. 2, pp. 161–167, 2013. View at Publisher · View at Google Scholar
  78. G. Thanassoulis, C. Y. Campbell, D. S. Owens et al., “Genetic associations with valvular calcification and aortic stenosis,” The New England Journal of Medicine, vol. 368, no. 6, pp. 503–512, 2013. View at Publisher · View at Google Scholar
  79. P. R. Kamstrup, A. Tybjærg-Hansen, and B. G. Nordestgaard, “Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population,” Journal of the American College of Cardiology, vol. 63, no. 5, pp. 470–477, 2014. View at Publisher · View at Google Scholar · View at Scopus
  80. B. J. Arsenault, S. M. Boekholdt, M. P. Dube et al., “Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective mendelian randomization study and replication in a case-control cohort,” Circulation: Cardiovascular Genetics, vol. 7, no. 3, pp. 304–310, 2014. View at Publisher · View at Google Scholar
  81. M.-Y. Hung, J. L. Witztum, and S. Tsimikas, “New therapeutic targets for calcific aortic valve stenosis: the lipoprotein(a)-lipoprotein-associated phospholipase A2-oxidized phospholipid axis,” Journal of the American College of Cardiology, vol. 63, no. 5, pp. 478–480, 2014. View at Publisher · View at Google Scholar · View at Scopus
  82. Y. I. Miller, S.-H. Choi, P. Wiesner et al., “Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity,” Circulation Research, vol. 108, no. 2, pp. 235–248, 2011. View at Publisher · View at Google Scholar · View at Scopus
  83. A. Mahmut, M.-C. Boulanger, D. El Husseini et al., “Elevated expression of lipoprotein-associated phospholipase A2 in calcific aortic valve disease: implications for valve mineralization,” Journal of the American College of Cardiology, vol. 63, no. 5, pp. 460–469, 2014. View at Publisher · View at Google Scholar · View at Scopus
  84. A. Mahmut, H. Mahjoub, M.-C. Boulanger et al., “Lp-PLA2 is associated with structural valve degeneration of bioprostheses,” European Journal of Clinical Investigation, vol. 44, no. 2, pp. 136–145, 2014. View at Publisher · View at Google Scholar · View at Scopus
  85. E. Nagy, D. C. Andersson, K. Caidahl et al., “Upregulation of the 5-lipoxygenase pathway in human aortic valves correlates with severity of stenosis and leads to leukotriene-induced effects on valvular myofibroblasts,” Circulation, vol. 123, no. 12, pp. 1316–1325, 2011. View at Publisher · View at Google Scholar · View at Scopus
  86. D. Poeckel and C. D. Funk, “The 5-lipoxygenase/leukotriene pathway in preclinical models of cardiovascular disease,” Cardiovascular Research, vol. 86, no. 2, pp. 243–253, 2010. View at Publisher · View at Google Scholar · View at Scopus
  87. J. H. Chen, W. L. K. Chen, K. L. Sider, C. Y. Yip, and C. A. Simmons, “β-catenin mediates mechanically regulated, transforming growth factor-β1-induced myofibroblast differentiation of aortic valve interstitial cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 3, pp. 590–597, 2011. View at Publisher · View at Google Scholar · View at Scopus
  88. J. D. Hutcheson, L. M. Ryzhova, V. Setola, and W. D. Merryman, “5-HT2B antagonism arrests non-canonical TGF-β1-induced valvular myofibroblast differentiation,” Journal of Molecular and Cellular Cardiology, vol. 53, no. 5, pp. 707–714, 2012. View at Publisher · View at Google Scholar · View at Scopus
  89. A. Mazzone, M. C. Epistolato, R. De Caterina et al., “Neoangiogenesis, T-lymphocyte infiltration, and heat shock protein-60 are biological hallmarks of an immunomediated inflammatory process in end-stage calcified aortic valve stenosis,” Journal of the American College of Cardiology, vol. 43, no. 9, pp. 1670–1676, 2004. View at Publisher · View at Google Scholar · View at Scopus
  90. A. Charest, A. Pépin, R. Shetty et al., “Distribution of SPARC during neovascularisation of degenerative aortic stenosis,” Heart, vol. 92, no. 12, pp. 1844–1849, 2006. View at Publisher · View at Google Scholar · View at Scopus
  91. M. Yoshioka, S. Yuasa, K. Matsumura et al., “Chondromodulin-I maintains cardiac valvular function by preventing angiogenesis,” Nature Medicine, vol. 12, no. 10, pp. 1151–1159, 2006. View at Publisher · View at Google Scholar · View at Scopus
  92. O. Fondard, D. Detaint, B. Iung et al., “Extracellular matrix remodelling in human aortic valve disease: the role of matrix metalloproteinases and their tissue inhibitors,” European Heart Journal, vol. 26, no. 13, pp. 1333–1341, 2005. View at Publisher · View at Google Scholar · View at Scopus
  93. I. Perrotta, E. Russo, C. Camastra et al., “New evidence for a critical role of elastin in calcification of native heart valves: Immunohistochemical and ultrastructural study with literature review,” Histopathology, vol. 59, no. 3, pp. 504–513, 2011. View at Publisher · View at Google Scholar · View at Scopus
  94. S. Helske, S. Syväranta, K. A. Lindstedt et al., “Increased expression of elastolytic cathepsins S, K, and V and their inhibitor cystatin C in stenotic aortic valves,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 8, pp. 1791–1798, 2006. View at Publisher · View at Google Scholar · View at Scopus
  95. E. Aikawa, M. Aikawa, G. Rusanescu et al., “Arterial and aortic valve calcification abolished by elastolytic cathepsin S deficiency in chronic renal disease,” Circulation, vol. 119, no. 13, pp. 1785–1794, 2009. View at Publisher · View at Google Scholar · View at Scopus
  96. R. Winchester, M. Wiesendanger, W. O'Brien et al., “Circulating activated and effector memory T cells are associated with calcification and clonal expansions in bicuspid and tricuspid valves of calcific aortic stenosis,” Journal of Immunology, vol. 187, no. 2, pp. 1006–1014, 2011. View at Publisher · View at Google Scholar · View at Scopus
  97. H. D. Wu, M. S. Maurer, R. A. Friedman et al., “The lymphocytic infiltration in calcific aortic stenosis predominantly consists of clonally expanded T cells,” The Journal of Immunology, vol. 178, no. 8, pp. 5329–5339, 2007. View at Publisher · View at Google Scholar · View at Scopus
  98. R. Wu, R. Giscombe, G. Holm, and A. K. Lefvert, “Induction of human cytotoxic T lymphocytes by oxidized low density lipoproteins,” Scandinavian Journal of Immunology, vol. 43, no. 4, pp. 381–384, 1996. View at Publisher · View at Google Scholar · View at Scopus
  99. C. Cote, P. Pibarot, J. P. Despres et al., “Association between circulating oxidised low-density lipoprotein and fibrocalcific remodelling of the aortic valve in aortic stenosis,” Heart, vol. 94, no. 9, pp. 1175–1180, 2008. View at Publisher · View at Google Scholar · View at Scopus
  100. S. Stemme, B. Faber, J. Holm, O. Wiklund, J. L. Witztum, and G. K. Hansson, “T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 9, pp. 3893–3897, 1995. View at Publisher · View at Google Scholar · View at Scopus
  101. P. M. Ridker, “Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT),” Journal of Thrombosis and Haemostasis, vol. 7, supplement 1, pp. 332–339, 2009. View at Publisher · View at Google Scholar · View at Scopus
  102. A. Bulgarelli, A. A. Martins Dias, B. Caramelli, and R. C. Maranhão, “Treatment with methotrexate inhibits atherogenesis in cholesterol-fed rabbits,” Journal of Cardiovascular Pharmacology, vol. 59, no. 4, pp. 308–314, 2012. View at Publisher · View at Google Scholar · View at Scopus
  103. M. R. Hurle, L. Yang, Q. Xie, D. K. Rajpal, P. Sanseau, and P. Agarwal, “Computational drug repositioning: from data to therapeutics,” Clinical Pharmacology & Therapeutics, vol. 93, no. 4, pp. 335–341, 2013. View at Publisher · View at Google Scholar · View at Scopus